Free accessResearch articleFirst published online 1994-2
In vitro Activity of Acyclic Nucleoside Phosphonate Derivatives against Feline Immunodeficiency Virus in Crandell Feline Kidney Cells and Feline Peripheral Blood Lymphocytes
Several novel fluorinated acyclic nucleoside phosphonates [i.e. 9-(3-fluoro-2-phosphonylmethoxy propyl)adenine (FPMPA) and 9-(3-fluoro-2-phosphonylmethoxypropyl)-2,6-diaminopurine (FPMPDAP)] were evaluated for their inhibitory effect against feline immunodeficiency virus (FIV) replication in Crandell feline kidney (CrFK) cells and feline peripheral blood lymphocytes (PBL) in vitro. Whereas 3-azido-3-deoxythymidine (AZT) was not able to achieve complete suppression of viral antigen expression and reverse transcriptase activity in the FIV-infected cell culture supernatants at 25 μM, FPMPA, FPMPDAP, and the 9-(2-phosphonylmethoxyethyl)purine derivatives PMEA and PMEDAP fully protected FIV-infected cells at μM. Both FPMPA and FPMPDAP were endowed with a higher antiviral potency and/or therapeutic selectivity than PMEA and PMEDAP in inhibiting FIV infection, mainly due to a markedly lower toxicity for the cell cultures.
References
1.
BabaM.TanakaH.De ClercqE.PauwelsR.BalzariniJ.ScholsD.NakashimaH.PernoC.-F.WalkerR.T., and MiyasakaT. (1989) Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem Biophys Res Commun165: 1375–1381.
2.
BalzariniJ.KangG.-J.DalaiM.HerdewijnP.De ClercqE.BroderS., and JohnsD.G. (1987) The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2′,3′-didehydro-2′,3′-dideoxyribonu-cleosides: a comparison with their parental 2′,3′-dideoxyribo-nucleosides. Mol Pharmacol32: 162–167.
3.
BalzariniJ.BabaM.PauwelsR.HerdewijnP., and De ClercqE. (1988) Anti-retrovirus activity of 3′-fluoro- and 3′-azido-substituted pyrimidine 2′,3′-dideoxynucleoside analogues. Biochem Pharmacol37: 2847–2856.
4.
BalzariniJ.NaesensL.HerdewijnP.RosenbergI.HolyA.PauwelsR.BabaM.JohnsD.G., and De ClercqE. (1989a) Marked in vivo antiretrovirus activity of 9-(2-phosphonylme-thoxyethyljadenine, a selective antihuman immunodeficiency virus agent. Proc Natl Acad Sci USA86: 332–336.
5.
BalzariniJ.van AerschotA.PauwelsR.BabaM.ScholsD.HerdewijnP., and De ClercqE. (1989b) 5-Halogeno-3′-fluoro-2′,3′-dideoxyuridines as inhibitors of human immunodeficiency virus (HIV): potent and selective anti-HIV activity of 3′-fluoro-2′,3′-dideoxy-5-chlorouridine. Mol Pharmacol35: 571–577.
6.
BalzariniJ.NaesensL., and De ClercqE. (1990) Anti-retrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in vivo increases when it is less frequently administered. Int J Cancer46: 337–340.
7.
BalzariniJ.HolyA.JindrichJ.DvorakovaH.HaoZ.SnoeckR.HerdewijnP.JohnsD.G., and De ClercqE. (1991a) 9-[(2RS)-3-fluoro-2-phosphonylmethoxypropyl] derivatives of purines: a class of highly selective antiretroviral agents in vitro and in vivo. Proc Natl Acad Sci USA88: 4961–4965.
8.
BalzariniJ.NaesensL.SlachmuyldersJ.NiphuisH.RosenbergI.HolyA.SchellekensH., and De ClercqE. (1991b) 9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys. AIDS5: 21–28.
9.
BalzariniJ.PernoC.-F.ScholsD., and De ClercqE. (1991c) Activity of acyclic nucleoside phosphonate analogues against human immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytes. Biochem Biophys Res Commun178: 329–335.
10.
BalzariniJ.Pérez-PérezM.-J.San-FélixA.ScholsD.PernoC.-F.VandammeA.-M.CamarasaM.-J., and De ClercqE. (1992a) 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide)pyrimidine (TSAO) nucleoside analogues: highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc Natl Acad Sci USA89: 4392–4396.
11.
BalzariniJ.HolyA.JindrichJ.NaesensL.SnoeckR.ScholsD., and De ClercqE. (1993) Differential antiherpesvirus antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: Potent and selective in vitro and in in vivo antiretrovirus activities of (fl)-9-(2-phosphonomethoxy-propyl)-2,6-diaminopurine. Antimicrob Agents Chemother37: 322–338.
12.
De ClercqE. (1991) Broad-spectrum anti-DNA virus and antiretrovirus activity of phosphonylmethoxyalkylpurines and -pyrimidines. Biochem Pharmacol42: 963–972.
13.
De ClercqE.HolyA., and RosenbergI. (1989) Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo. Antimicrob Agents Chemother33: 185–191.
14.
EgberinkH.BorstM.NiphuisH.BalzariniJ.NeuH.SchellekensH.De ClercqE.HorzinekM., and KoolenM. (1990) Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine. Proc Natl Acad Sci USA87: 3087–3091.
15.
FauldsD., and BrogdenR.N. (1992) Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. DrugsA4: 94–116.
16.
GoldmanM.E.NumbergJ.H.O'BrienJ.A.QuinteroJ.C.SchleifW.A.FreundK.F.GaulS.L.SaariW.S.WaiJ.S.HoffmanJ.M.AndersonP.S.HupeD.J.EminiE.A., and SternA.M. (1991) Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci USA88: 6863–6867.
17.
HarbourD.A.WilliamsP.D.Gruyffydd-JonesT.J.BurbridgeJ., and PearsonG.R. (1988) Isolation of a T-lymphotropic lentivirus from a persistently leucopenic domestic cat. Vet Rec122: 84–86.
18.
HartmannK., and HinzeK. (1991) Epidemiologie und Klinik der FIV-lnfektion in Bayern. Tierärtzl Prax19: 545–551.
19.
HartmannK.DonathA.BeerB.EgberinkH.F.HorzinekM.C.LutzH.Hoffmann-FezerG.ThumI., and ThefeldS. (1992) Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms. Vet Immunol Immunopathol35: 167–175.
20.
HerdewijnP.BalzariniJ.De ClercqE.PauwelsR.BabaM.BroderS., and VanderhaegheH. (1987) 3′-Substituted 2′,3′-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents. J Med Chem30: 1270–1278.
21.
HolyA., and RosenbergI. (1987) Synthesis of 9-(2-phosphonylmethoxyethyl)adenine and related compounds. Collect Czech Chem Commun52: 2801–2809.
22.
HolyA.VotrubaI.MertaA.CernyJ.VeselyJ.VlachJ.SedivaK.RosenbergI.OtmarM.HrebabeckyH.Trav-NicekM.VonkaV.SnoeckR., and De ClercqE. (1990) Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro. Antiviral Res13: 295–312.
23.
IshidaT.WashizuT.ToriyabeK.MotoyoshiS.TomodaI., and PetersenN.C. (1989) Feline immunodeficiency virus infection in cats of Japan. J Am Vet Med Assoc194: 221–225.
24.
KuklaM.J.BreslinH.J.PauwelsR.FeddeC.L.MirandaM.ScottM.K.SherrillR.G.RaeymaekersA.van GelderJ.AndriesK.JanssenM.A.C.De ClercqE., and JanssenP.A.J. (1991) Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin 2(1H)-one (TIBO) derivatives. J Med Chem34: 746–751.
25.
MerluzziV.J.HargraveK.D.LabadiaM.GrozingerK.SkoogM.WuJ.C.ShihC.-K.EcknerK.HattoxS.AdamsJ.RosenthalA.S.FaanesR.EcknerR.J.KoupR.A., and SullivanJ.L. (1990) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science250: 1411–1413.
26.
MitsuyaH., and BroderS. (1986) Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc Natl Acad Sci USA83: 1911–1915.
27.
MitsuyaH.WeinholdK.J.FurmanP.A.St. ClairM.H.LehrmanS. NusinoffGalloR.C.BolognesiD.BarryD.W., and BroderS. (1985) 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA82: 7096–7100.
28.
NaesensL.BalzariniJ.RosenbergI.HolyA., and De ClercqE. (1989) 9-(2-Phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP): a novel agent with anti-human immunodeficiency virus activity in vitro and potent anti Moloney murine sarcoma virus activity in vivo. Eur J Clin Microbiol Infect Dis8: 1043–1047.
29.
NaesensL.BalzariniJ., and De ClercqE. (1991) Single-dose administration of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the prophylaxis of retrovirus infection in vivo. Antiviral Res16: 53–64.
30.
NorthT.W.NorthG.T., and PedersenN.C. (1989) Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome. Antimicrob Agents Chemother33: 915–919.
31.
OlmstedR.A.BarnesA.K.YamamotoJ.K.HirschV.M.PurcellR.H., and JohnsonP.R. (1989a) Molecular cloning of feline immunodeficiency virus. Proc Natl Acad Sci USA86: 2448–2452.
32.
OlmstedR.A.HirschV.M.PurcellR.H., and JohnsonP.R. (1989b) Nucleotide sequence analysis of feline immunodeficiency virus: genome organization and relationship to other lentiviruses. Proc Natl Acad Sci USA86: 8088–8092.
33.
PauwelsR.BalzariniJ.ScholsD.BabaM.DesmyterJ.RosenbergI.HolyA., and De ClercqE. (1988) Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob Agents Chemother32: 1025–1030.
34.
PauwelsR.AndriesK.DesmyterJ.ScholsD.KuklaM.J.BreslinH.J.RaeymaeckersA.van GelderJ.WoestenborghsR.HeykantsJ.SchellekensK.JanssenM.A.C.De ClercqE., and JanssenP.A.J. (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature343: 470–474.
35.
PauwelsR.AndriesK.DebyserZ.van DaeleP.ScholsD.VandammeA.-M.StoffelsP.De VreeseK.WoestenborghsR.JanssenC.G.M.AnneJ.CauwenberghG.DesmyterJ.HeykantsJ.JanssenM.A.C.De ClercqE., and JanssenP.A.J. (1992) Potent and highly selective HIV-1 inhibition by a new series of α-anilino phenyl acetamide (α-APA) derivatives targeted at HIV-1 reverse transcriptase. Proc Natl Acad Sci USA, in press.
36.
PedersenN.C.HoE.M.BrownM.L., and YamamotoJ.K. (1987) Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science235: 790–793.
37.
PedersenN.C.YamamotoJ.K.IshidaT., and HansenH. (1989) Feline immunodeficiency virus infection. Vet Immunol Immunopathol21: 111–129.
38.
RichmanD.D.FischlM.A.GriecoM.H.GottliebM.S.VolberdingP.A.LaskinO.L.LeedomJ.M.GroopmanJ.E.MildvanD.HirschM.S.JacksonG.G.DurackD.T., Nusinoff-Lehrman, S., and the AZT Collaborative Working Group (1987) The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex; a double-blind, placebo-controlled trial. New Engl J Med317: 185–191.
39.
RomeroD.L.BussoM.TanC.-K.ReusserF.PalmerJ.R.PoppeS.M.AristoffP.A.DowneyK.M.SoA.G.ResnickL., and TarpleyW.G. (1991) Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA88: 8806–8810.
40.
TalbottR.L.SpargerE.E.LovelaceK.M.FitchW.M.PedersenN.C.LuciwP.A., and ElderJ.H. (1989) Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc Natl Acad Sci USA86: 5743–5747.
41.
YarchoanR., and BroderS. (1989) Anti-retroviral therapy of AIDS and related disorders: general principles and specific development of dideoxynucleosides. Pharmacol Therap40: 329–348.
42.
YarchoanR.PernoC.F.ThomasR.V.KleckerR.W.AllainJ.-P.WillsR.J.McAteeN.FischlM.A.DubinskyR.McNeelyM.C.MitsuyaH.PludaJ.M.LawleyT.J.LeutherM.SafaiB.CollinsJ.M.MyersC.E., and BroderS. (1988) Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lanceti: 76–81.
43.
YarchoanR.MitsuyaH.MyersC.E., and BroderS. (1989) Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. New Engl J Med321: 726–738.
